search
Back to results

Effect of CoQ10 on the Outcome of MAFLD Patients

Primary Purpose

Fatty Liver, NAFLD

Status
Not yet recruiting
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
Coenzyme Q10 Forte® capsules
Sponsored by
Ain Shams University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Fatty Liver focused on measuring Coenzyme Q10, Liver steatosis, TNF alpha, Fatty Liver, Inflammation, MAFLD, CoQ10, Ubiquinone, Liver Disease

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: All study subjects and prior to consenting to the ICF, laboratory and imaging work-up will be evaluated for the presence of three out of five criteria for metabolic dysregulation in the context of metabolic -dysfunction associated fatty liver disease (MAFLD): Waist circumference (WC) ≥ 102/88 cm for men and women respectively. HDL cholesterol <40 mg/dl in men and <50 mg/dl in women or on specific drug therapy. Plasma Triglycerides ≥ 150 mg/dl or on specific drug therapy. Blood pressure ≥130 and/or ≥ 85 or on specific anti-hypertensive therapy. Fasting blood glucose ≥ 100 mg/dl or on specific anti hyperglycemic therapy Patients who agree to sign an informed consent Adult patients >18 years old. Males and females Willing to comply with procedures and follow up Elevated serum transaminases (1-4 times the ULN) Imaging evidence of fatty liver: pelviabdominal ultrasound and Fibro- CAP study Exclusion Criteria: Pregnancy or lactating Physical or mental abnormalities HCV infection HBV infection Anaemia Thrombocytopenia Haematological malignancies Ongoing alcoholism (Male: >30g/day, Female: >20g/day) Patients with renal failure Autoimmune hepatitis Celiac disease Wilson's disease Hemochromatosis Drugs: Tamoxifen, Valproic acid, Amiodarone, Methotrexate, Steroids, Anticoagulants, All anti-oxidative stress agents, Cos, IUD Chronic use of systematically immunosuppressive agent or drugs that can affect liver profile. Hypo/Hyper-thyroidism Bypass surgeries TPN (Total Parenteral Nutrition)

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    No Intervention

    Experimental

    Arm Label

    Control group

    Test Group

    Arm Description

    Patients will receive the standard conventional care which is mainly therapeutic life changes

    Patients will receive Coenzyme Q10 Forte® (MEPACO Pharmaceutical Company, Cairo, Egypt) capsules in a dose of 100 mg twice per day 1 capsule every 12 hours for twelve weeks, in addition to the standard conventional care.

    Outcomes

    Primary Outcome Measures

    Change in liver steatosis degree
    Improvement in steatosis degree will be assessed using Fibro-CAP scoring measured in decibels per meter (dB/m) and ranges from 100-400, where 238 to 260 dB/m represents 11-33% fatty change in the liver, 260 to 290 dB/m represents 34-66% fatty change in the liver and > 290 dB/m represents almost 67% or more fatty change in the liver.

    Secondary Outcome Measures

    Change in serum levels of liver transaminases (AST and ALT) 3 months post treatment with Coenzyme Q10
    Levels of alanine transaminase (ALT) and aspartate aminotransferase (AST) will be measured in serum where normal serum ALT is 7-56 U/L and normal serum AST is 0 to 35 U/L.
    Change in serum levels of tumor necrosis factor-alpha (TNF-α) 3 months post treatment with Coenzyme Q10
    TNF-α levels will be assessed in serum
    Change in the quality of life of MAFLD patients
    Quality of life will be assessed using the Chronic Liver Disease (CLD) questionnaire
    Study the drug's effect on kidney functions by measuring serum creatinine levels
    Serum creatinine levels will be measured where the normal range is 0.74 to 1.35 mg/dL (61.9 to 114.9 µmol/L) for men and 0.59 to 1.04 mg/dL (53 to 97.2 µmol/L) for women

    Full Information

    First Posted
    August 1, 2023
    Last Updated
    August 8, 2023
    Sponsor
    Ain Shams University
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05984745
    Brief Title
    Effect of CoQ10 on the Outcome of MAFLD Patients
    Official Title
    Effect of Coenzyme Q10 on the Outcome of Metabolic Dysfunction-Associated Fatty Liver Disease Patients
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    August 2023
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    September 2023 (Anticipated)
    Primary Completion Date
    September 2024 (Anticipated)
    Study Completion Date
    December 2024 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Ain Shams University

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No

    5. Study Description

    Brief Summary
    So far there has been no universal treatment for MAFLD since it has a complex etiology that involves ethnic, genetic, metabolic and environmental factors. However, therapeutic life changes including: diet, weight loss, and physical activity remain the cornerstone of treatment and is recommended by both American and European associations. Inflammatory biomarkers, such as tumor necrosis factor-alpha, and adipokines play key roles in the pathogenesis of MAFLD, hence, the anti-inflammatory and antioxidant effects of coenzyme Q10 especially at high doses that have not been tested are hypothesized to have a beneficial role in improving the systemic inflammation and biochemical variables. This study is conducted to test this hypothesis
    Detailed Description
    The liver disease with the most continuously rising prevalence rates is metabolic-dysfunction associated fatty liver disease (MAFLD), making us arrive at a conclusion that it might be the liver disease epidemic of the 21st century. It is increasingly diagnosed in many developed and developing countries and is considered the most common cause of chronic liver disease among patients with type 2 diabetes mellitus (T2DM). By 2030, it will be the leading cause for hepatocellular carcinoma (HCC) related liver transplantation (LTx) in western countries. A number of studies have suggested that metabolic associated co-morbidities, such as obesity, type 2 DM, CVD, dyslipidemia, hypertension, metabolic syndrome, hypothyroidism, OSAS, PCOS are major risk factors for MAFLD. It encompasses a wide spectrum of histological pattern, ranging from simple steatosis to steatohepatitis, fibrosis and cirrhosis. The global prevalence of MAFLD is currently estimated to be 25%, but the highest rates are reported from the Middle East 31.8% and South America 30.5%, followed by Asia 27.4%, the USA 24% and Europe 23.7%, whereas MAFLD is less common in Africa 13.5%. Coenzyme Q10 (CoQ10) or ubiquinone is a lipid-soluble and vitamin-like compound, which acts as a pivotal cofactor in the mitochondrial respiratory chain in addition to its role as a natural scavenger of free radicals. It is synthesized by cells of the body and also found in abundance in the human diet. Recent evidence suggests that CoQ10 supplementation might be useful in improving and preventing pathological conditions such as metabolic syndrome, hypertension, diabetes, liver diseases, and insulin resistance Because of its antioxidant activity, it seems that CoQ10 can prevent activation of the inflammatory signaling pathway. Many studies have shown that administration of CoQ10 reduced hepatic oxidative stress and inflammation. Also, other studies observed that CoQ10 supplementation reduced TNF-α production and serum levels of liver aminotransferase and decreased NF-kB expression. In addition, a previously published study showed that a dose of 100 mg/day of CoQ10 for 4 weeks can improve serum AST levels, total antioxidant capacity and waist circumference, but it had a non-significant effect on insulin resistance and MDA levels. The same result was found in the study by Esfahani et al. reporting improvement in AST and ALT concentrations and lower grades of portal inflammation and hepatocellular liver necrosis in thioacetamide-induced liver damage in rats. Yet, some contradicting results were reported by Hodgson et al. were they found a non-significant reduction in body weight after CoQ10 supplementation in patients with T2DM. These contradictions were addressed by Faresi et al. where they tested the effect of the same oral dose of CoQ10 used by Farhangi et al. for 12 weeks, where it had beneficial effects on serum levels of TNF-a, hs-CRP, hepatic enzymes, adiponectin, and NAFLD grades as well as near-significant changes in serum leptin among patients with NAFLD. However, serum IL-6 levels and AAR remained unchanged after CoQ10 supplementation. Till this day, only a few small studies tried to investigate the effect of CoQ10 administration on the degree of steatosis in MAFLD patients and their results failed to show a clear effect, due to the conflicting and limited data. Hence, this encouraged us to study the efficacy and tolerability of a higher dose of CoQ10 especially that it can be safely administered up to a dose of 1200 mg/day. In addition, CoQ10 showed promising effects in previous studies, so the general recommendation was to study its effect in a larger study population, for longer periods.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Fatty Liver, NAFLD
    Keywords
    Coenzyme Q10, Liver steatosis, TNF alpha, Fatty Liver, Inflammation, MAFLD, CoQ10, Ubiquinone, Liver Disease

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 2
    Interventional Study Model
    Parallel Assignment
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    166 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Control group
    Arm Type
    No Intervention
    Arm Description
    Patients will receive the standard conventional care which is mainly therapeutic life changes
    Arm Title
    Test Group
    Arm Type
    Experimental
    Arm Description
    Patients will receive Coenzyme Q10 Forte® (MEPACO Pharmaceutical Company, Cairo, Egypt) capsules in a dose of 100 mg twice per day 1 capsule every 12 hours for twelve weeks, in addition to the standard conventional care.
    Intervention Type
    Drug
    Intervention Name(s)
    Coenzyme Q10 Forte® capsules
    Intervention Description
    Coenzyme Q10 in the form of soft gelatin capsules, each capsule containing 100 mg
    Primary Outcome Measure Information:
    Title
    Change in liver steatosis degree
    Description
    Improvement in steatosis degree will be assessed using Fibro-CAP scoring measured in decibels per meter (dB/m) and ranges from 100-400, where 238 to 260 dB/m represents 11-33% fatty change in the liver, 260 to 290 dB/m represents 34-66% fatty change in the liver and > 290 dB/m represents almost 67% or more fatty change in the liver.
    Time Frame
    Baseline and at 12 weeks
    Secondary Outcome Measure Information:
    Title
    Change in serum levels of liver transaminases (AST and ALT) 3 months post treatment with Coenzyme Q10
    Description
    Levels of alanine transaminase (ALT) and aspartate aminotransferase (AST) will be measured in serum where normal serum ALT is 7-56 U/L and normal serum AST is 0 to 35 U/L.
    Time Frame
    Baseline and at 12 weeks
    Title
    Change in serum levels of tumor necrosis factor-alpha (TNF-α) 3 months post treatment with Coenzyme Q10
    Description
    TNF-α levels will be assessed in serum
    Time Frame
    Baseline and at 12 weeks
    Title
    Change in the quality of life of MAFLD patients
    Description
    Quality of life will be assessed using the Chronic Liver Disease (CLD) questionnaire
    Time Frame
    Baseline and at 12 weeks
    Title
    Study the drug's effect on kidney functions by measuring serum creatinine levels
    Description
    Serum creatinine levels will be measured where the normal range is 0.74 to 1.35 mg/dL (61.9 to 114.9 µmol/L) for men and 0.59 to 1.04 mg/dL (53 to 97.2 µmol/L) for women
    Time Frame
    Baseline and at 12 weeks

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    80 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: All study subjects and prior to consenting to the ICF, laboratory and imaging work-up will be evaluated for the presence of three out of five criteria for metabolic dysregulation in the context of metabolic -dysfunction associated fatty liver disease (MAFLD): Waist circumference (WC) ≥ 102/88 cm for men and women respectively. HDL cholesterol <40 mg/dl in men and <50 mg/dl in women or on specific drug therapy. Plasma Triglycerides ≥ 150 mg/dl or on specific drug therapy. Blood pressure ≥130 and/or ≥ 85 or on specific anti-hypertensive therapy. Fasting blood glucose ≥ 100 mg/dl or on specific anti hyperglycemic therapy Patients who agree to sign an informed consent Adult patients >18 years old. Males and females Willing to comply with procedures and follow up Elevated serum transaminases (1-4 times the ULN) Imaging evidence of fatty liver: pelviabdominal ultrasound and Fibro- CAP study Exclusion Criteria: Pregnancy or lactating Physical or mental abnormalities HCV infection HBV infection Anaemia Thrombocytopenia Haematological malignancies Ongoing alcoholism (Male: >30g/day, Female: >20g/day) Patients with renal failure Autoimmune hepatitis Celiac disease Wilson's disease Hemochromatosis Drugs: Tamoxifen, Valproic acid, Amiodarone, Methotrexate, Steroids, Anticoagulants, All anti-oxidative stress agents, Cos, IUD Chronic use of systematically immunosuppressive agent or drugs that can affect liver profile. Hypo/Hyper-thyroidism Bypass surgeries TPN (Total Parenteral Nutrition)
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Mariam Seif
    Phone
    +201112720114
    Email
    mariam.talaat@pharma.asu.edu.eg

    12. IPD Sharing Statement

    Plan to Share IPD
    Undecided
    Citations:
    PubMed Identifier
    28930295
    Citation
    Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, George J, Bugianesi E. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018 Jan;15(1):11-20. doi: 10.1038/nrgastro.2017.109. Epub 2017 Sep 20.
    Results Reference
    background
    PubMed Identifier
    28941364
    Citation
    Allen AM, Therneau TM, Larson JJ, Coward A, Somers VK, Kamath PS. Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: A 20 year-community study. Hepatology. 2018 May;67(5):1726-1736. doi: 10.1002/hep.29546. Epub 2018 Mar 23.
    Results Reference
    background
    PubMed Identifier
    25477264
    Citation
    McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol. 2015 May;62(5):1148-55. doi: 10.1016/j.jhep.2014.11.034. Epub 2014 Dec 1.
    Results Reference
    background
    PubMed Identifier
    26707365
    Citation
    Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016 Jul;64(1):73-84. doi: 10.1002/hep.28431. Epub 2016 Feb 22.
    Results Reference
    background
    PubMed Identifier
    24932457
    Citation
    Alam MA, Rahman MM. Mitochondrial dysfunction in obesity: potential benefit and mechanism of Co-enzyme Q10 supplementation in metabolic syndrome. J Diabetes Metab Disord. 2014 May 23;13:60. doi: 10.1186/2251-6581-13-60. eCollection 2014.
    Results Reference
    background
    PubMed Identifier
    17173569
    Citation
    Fuller B, Smith D, Howerton A, Kern D. Anti-inflammatory effects of CoQ10 and colorless carotenoids. J Cosmet Dermatol. 2006 Mar;5(1):30-8. doi: 10.1111/j.1473-2165.2006.00220.x.
    Results Reference
    background
    PubMed Identifier
    19632207
    Citation
    Sohet FM, Neyrinck AM, Pachikian BD, de Backer FC, Bindels LB, Niklowitz P, Menke T, Cani PD, Delzenne NM. Coenzyme Q10 supplementation lowers hepatic oxidative stress and inflammation associated with diet-induced obesity in mice. Biochem Pharmacol. 2009 Dec 1;78(11):1391-400. doi: 10.1016/j.bcp.2009.07.008. Epub 2009 Jul 23.
    Results Reference
    background
    PubMed Identifier
    22408414
    Citation
    Bravo E, Palleschi S, Rossi B, Napolitano M, Tiano L, D'Amore E, Botham KM. Coenzyme Q metabolism is disturbed in high fat diet-induced non-alcoholic fatty liver disease in rats. Int J Mol Sci. 2012;13(2):1644-1657. doi: 10.3390/ijms13021644. Epub 2012 Feb 2.
    Results Reference
    background
    PubMed Identifier
    24130601
    Citation
    Ashkani Esfahani S, Esmaeilzadeh E, Bagheri F, Emami Y, Farjam M. The effect of co-enzyme q10 on acute liver damage in rats, a biochemical and pathological study. Hepat Mon. 2013 Aug 27;13(8):e13685. doi: 10.5812/hepatmon.13685. eCollection 2013. No abstract available.
    Results Reference
    background
    PubMed Identifier
    26156412
    Citation
    Farsi F, Mohammadshahi M, Alavinejad P, Rezazadeh A, Zarei M, Engali KA. Functions of Coenzyme Q10 Supplementation on Liver Enzymes, Markers of Systemic Inflammation, and Adipokines in Patients Affected by Nonalcoholic Fatty Liver Disease: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial. J Am Coll Nutr. 2016 May-Jun;35(4):346-53. doi: 10.1080/07315724.2015.1021057. Epub 2015 Jul 9.
    Results Reference
    background

    Learn more about this trial

    Effect of CoQ10 on the Outcome of MAFLD Patients

    We'll reach out to this number within 24 hrs